Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 20/20 | 0.63 |
| ▸ | HCRTR2 | O43614 | 20/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22666385 | 1.00 | HCRTR1 (0.63) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL2610459 | 0.90 | HCRTR1 (0.60) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL19866895 | 0.88 | HCRTR1 (0.60) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL29521573 | 0.87 | HCRTR1 (0.63) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL22666389 | 0.87 | HCRTR1 (0.63) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL2116673 | 0.87 | HCRTR1 (0.63) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL19124706 | 0.87 | HCRTR1 (0.63) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL26351279 | 0.85 | HCRTR1 (0.74) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL26350983 | 0.85 | HCRTR1 (0.74) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL24533939 | 0.83 | HCRTR1 (0.74) | HCRTR1HCRTR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194925-A1 | METHOD AND COMPOUND USEFUL IN PREPARATION OF OREXIN-2 RECEPTOR ANTAGONIST, AND LEMBOREXANT HAVING FEW IMPURITIES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-23 | — | — | US | disclosed |
| US-20220194925-A1 | METHOD AND COMPOUND USEFUL IN PREPARATION OF OREXIN-2 RECEPTOR ANTAGONIST, AND LEMBOREXANT HAVING FEW IMPURITIES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-23 | — | — | US | disclosed |
| CN-113727962-A | Methods and compounds for preparing orexin-2 receptor antagonists and lebereproduction with reduced impurities | 卫材R&D管理有限公司 | 2021-11-30 | — | — | CN | disclosed |
| WO-2020230800-A1 | METHOD AND COMPOUND USEFUL IN PREPARATION OF OREXIN-2 RECEPTOR ANTAGONIST, AND LEMBOREXANT HAVING FEW IMPURITIES | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2020-11-19 | — | — | WO | disclosed |
| EP-3178814-B1 | METHOD FOR PRODUCING PYRIMIDIN-1-OL COMPOUND, AND INTERMEDIATE THEREOF | EISAI R&D MAN CO LTD (JP) | 2019-04-10 | — | — | EP | disclosed |
| EP-2814798-B1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF OREXIN-2 RECEPTOR ANTAGONISTS | EISAI R&D MAN CO LTD (JP) | 2019-04-03 | — | — | EP | disclosed |
| US-20180044285-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF OREXIN-2 RECEPTOR ANTAGONISTS | EISAI R&D MAN CO LTD (JP) | 2018-02-15 | — | — | US | disclosed |
| US-9828336-B2 | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-11-28 | — | — | US | disclosed |
| US-9828336-B2 | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-11-28 | — | — | US | disclosed |
| US-20170204068-A1 | METHOD FOR PRODUCING PYRIMIDINE-1-OL COMPOUND, AND INTERMEDIATE THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-07-20 | — | — | US | disclosed |
| US-20170204068-A1 | METHOD FOR PRODUCING PYRIMIDINE-1-OL COMPOUND, AND INTERMEDIATE THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-07-20 | — | — | US | disclosed |
| EP-3178814-A1 | METHOD FOR PRODUCING PYRIMIDIN-1-OL COMPOUND, AND INTERMEDIATE THEREOF | Eisai R&D Management Co., Ltd. (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-20160318858-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF OREXIN-2 RECEPTOR ANTAGONISTS | EISAI R&D MAN CO LTD (JP) | 2016-11-03 | — | — | US | disclosed |
| US-20160318858-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF OREXIN-2 RECEPTOR ANTAGONISTS | EISAI R&D MAN CO LTD (JP) | 2016-11-03 | — | — | US | disclosed |
| US-9416109-B2 | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-08-16 | — | — | US | disclosed |
| US-9416109-B2 | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-08-16 | — | — | US | disclosed |
| US-20150025237-A1 | Methods and Compounds Useful in the Synthesis of Orexin-2 Receptor Antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-22 | — | — | US | disclosed |
| US-20150025237-A1 | Methods and Compounds Useful in the Synthesis of Orexin-2 Receptor Antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-22 | — | — | US | disclosed |
| US-8901153-B2 | Pesticidal compositions and processes related thereto | DOW AGROSCIENCES, LLC. (US) | 2014-12-02 | — | — | US | disclosed |
| WO-2013123240-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF OREXIN-2 RECEPTOR ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD (JP) | 2013-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194925-A1 | METHOD AND COMPOUND USEFUL IN PREPARATION OF OREXIN-2 RECEPTOR ANTAGONIST, AND LEMBOREXANT HAVING FEW IMPURITIES | HCRTR2, HCRTR1, MCHR2 | HCRTR1 2/4885HCRTR2 1/4885KCNH2 1380/4885 |
| US-20150025237-A1 | Methods and Compounds Useful in the Synthesis of Orexin-2 Receptor Antagonists | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885HCRTR2 1/4885KCNH2 2306/4885 |
| US-20170204068-A1 | METHOD FOR PRODUCING PYRIMIDINE-1-OL COMPOUND, AND INTERMEDIATE THEREOF | DPYD, UMPS, TYMS | HCRTR1 4807/4885HCRTR2 4720/4885KCNH2 3811/4885 |
| US-20180044285-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF OREXIN-2 RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885HCRTR2 1/4885KCNH2 2306/4885 |
| US-20160318858-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF OREXIN-2 RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885HCRTR2 1/4885KCNH2 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.